139 related articles for article (PubMed ID: 38534109)
1. CMV-RNAemia as new marker of active viral replication in transplant recipients.
Piccirilli G; Lanna F; Gabrielli L; Motta V; Franceschiello M; Cantiani A; Pavoni M; Leone M; Borgatti EC; Gibertoni D; Pascale R; Giannella M; Bonifazi F; Lazzarotto T
J Clin Microbiol; 2024 May; 62(5):e0163023. PubMed ID: 38534109
[No Abstract] [Full Text] [Related]
2. A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients.
Lehto JT; Lemström K; Halme M; Lappalainen M; Lommi J; Sipponen J; Harjula A; Tukiainen P; Koskinen PK
Transpl Int; 2005 Dec; 18(12):1318-27. PubMed ID: 16297050
[TBL] [Abstract][Full Text] [Related]
3. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
4. An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.
Talaya A; Giménez E; Pascual MJ; Gago B; Piñana JL; Hernández-Boluda JC; Vázquez L; García M; Serrano D; Hernández M; Albert E; Solano C; Navarro D
Med Microbiol Immunol; 2020 Feb; 209(1):15-21. PubMed ID: 31478067
[TBL] [Abstract][Full Text] [Related]
5. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
Stoelben S; Arns W; Renders L; Hummel J; Mühlfeld A; Stangl M; Fischereder M; Gwinner W; Suwelack B; Witzke O; Dürr M; Beelen DW; Michel D; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Budde K
Transpl Int; 2014 Jan; 27(1):77-86. PubMed ID: 24164420
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Cytomegalovirus disease and viral replication kinetics in seropositive liver transplant recipients managed under preemptive therapy in a tertiary-care center in Mexico City: a retrospective cohort study.
Fernández-García OA; García-Juárez I; Belaunzarán-Zamudio PF; Vilatoba M; Wisniowski-Yáñez A; Salomón-Ávila J; Bobadilla-Del-Valle M; Sifuentes-Osornio J; Cuellar-Rodríguez JM
BMC Infect Dis; 2022 Feb; 22(1):155. PubMed ID: 35164684
[TBL] [Abstract][Full Text] [Related]
7. Acute and Chronic Changes in Gene Expression After CMV DNAemia in Kidney Transplant Recipients.
Ahn R; Schaenman J; Qian Z; Pickering H; Groysberg V; Rossetti M; Llamas M; Hoffmann A; Gjertson D; Deng M; Bunnapradist S; Reed EF;
Front Immunol; 2021; 12():750659. PubMed ID: 34867983
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of a quantitative assay detecting cytomegalovirus transcripts for preemptive therapy in allogeneic hematopoietic stem cell transplant recipients.
Ishii K; Onishi Y; Miyamura N; Fukuhara N; Ishizawa K; Nakanishi M; Ohnaka S; Miyasaka T; Kanno E; Kawakami K; Harigae H; Kaku M
J Med Virol; 2017 Jul; 89(7):1265-1273. PubMed ID: 28165158
[TBL] [Abstract][Full Text] [Related]
9. Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients.
Maggi F; Focosi D; Statzu M; Bianco G; Costa C; Macera L; Spezia PG; Medici C; Albert E; Navarro D; Scagnolari C; Pistello M; Cavallo R; Antonelli G
Sci Rep; 2018 Oct; 8(1):15490. PubMed ID: 30341363
[TBL] [Abstract][Full Text] [Related]
10. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.
Phoompoung P; Ferreira VH; Tikkanen J; Husain S; Viswabandya A; Kumar D; Humar A
Transplantation; 2020 Feb; 104(2):404-409. PubMed ID: 32000236
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus infection in a seroendemic renal transplant population: a longitudinal study of virological markers.
Rao M; Finny GJ; Abraham P; Juneja R; Thomas PP; Jacob CK; Sridharan G
Nephron; 2000 Apr; 84(4):367-73. PubMed ID: 10754415
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients.
Badley AD; Patel R; Portela DF; Harmsen WS; Smith TF; Ilstrup DM; Steers JL; Wiesner RH; Paya CV
J Infect Dis; 1996 Feb; 173(2):446-9. PubMed ID: 8568308
[TBL] [Abstract][Full Text] [Related]
14. The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation.
Reischig T; Kacer M; Hruba P; Jindra P; Hes O; Lysak D; Bouda M; Viklicky O
Antivir Ther; 2017; 22(6):503-513. PubMed ID: 28091392
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients.
Pascual T; Solano C; Torres I; Talaya A; Giménez E; Vinuesa V; Piñana JL; Hernández-Boluda JC; Pérez A; Navarro D
J Med Virol; 2018 Aug; 90(8):1375-1382. PubMed ID: 29663435
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
Pearston AP; Ingemi AI; Ripley K; Wilson TJ; Gruber J; McMahon M; Sutton S; Khardori N
Transplant Proc; 2021 May; 53(4):1284-1287. PubMed ID: 33715819
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus diagnosis in renal and bone marrow transplant recipients: the impact of molecular assays.
Halwachs-Baumann G; Wilders-Truschnig M; Enzinger G; Eibl M; Linkesch W; Dornbusch HJ; Santner BI; Marth E; Kessler HH
J Clin Virol; 2001 Jan; 20(1-2):49-57. PubMed ID: 11163583
[TBL] [Abstract][Full Text] [Related]
19. Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting.
Giménez E; Blanco-Lobo P; Muñoz-Cobo B; Solano C; Amat P; Pérez-Romero P; Navarro D
J Gen Virol; 2015 Sep; 96(9):2822-2831. PubMed ID: 26025872
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
Sahin DG; Gunduz E; Kasifoglu N; Akay OM; Us T; Gulbas Z
Adv Ther; 2013 Aug; 30(8):784-91. PubMed ID: 23959787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
